Clinical Trial

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

Name: A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324 — clinical trial record (NCT07484074)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: JADE

Completed Phase 1

View on ClinicalTrials.gov →

Summary

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

Trial Details

NCT Number	NCT07484074
Lead Sponsor	Ollin Biosciences, Inc.
Conditions	Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
Enrollment	164 participants
Start Date	2025-02-12
Primary Completion	2025-10-10 (estimated)
Study Completion	2025-12-09 (estimated)
Updated on ClinicalTrials.gov	2026-03-19